The Goldilocks Isotope? Why Astatine-211 Might Be Just Right for Radiotherapeutics

In this episode, Milton Lönnroth, Co-Founder and CEO, shares how Atley Solutions is changing the game for astatine-211, a promising isotope in cancer therapy. Atley supports radiopharmaceutical companies and researchers by enabling the scalable production and labeling of astatine-based compounds. Milton explains how the company's roots in the University of Gothenburg’s alpha therapy group shaped a mission focused squarely on patient needs, especially for challenging cancers like metastatic ovarian cancer. The company's first commercial product, the C100 module, automates the purification, labeling, and preparation of astatine-211 drug products, significantly lowering the barrier to entry for researchers and clinical developers alike.Milton dives deep into what makes astatine-211 uniquely suited for targeted radiotherapy. Its simple decay scheme, pure alpha emissions, and lack of hard gamma radiation allow for more precise treatment with fewer safety hurdles, enabling outpatient care and reducing the need for bulky shielding infrastructure. The show also explores the logistical and chemical advantages of astatine’s halogen status, its compatibility with small molecules, and the potential to reach hard-to-treat cancers like glioblastoma and neuroblastoma. Milton turns criticism of At-211’s short half-life on its head, arguing that astatine offers a “Goldilocks” balance, perfect for scalable and environmentally sound therapeutic use.Milton is optimistic about At-211’s role in advancing curative cancer care. With Atley’s technology entering clinical trials and commercial momentum building, he foresees a broader pipeline of alpha therapies reaching patients worldwide. He also emphasizes the importance of infrastructure and workforce development to support this growth and raises a call-to-action for the industry to invest in radiopharmacy readiness and training. Whether it’s reducing relapse rates in ovarian cancer or unlocking treatment options for children with aggressive cancers, Milton and his team at Atley are working hard to give astatine a leading role in defining the next era of nuclear medicine.—-----Time Stamps:*(02:25 The Origin Story of Atley Solutions*(04:34)  Clinical Trials and Seeing Promising Results*(08:17) The E100 Module: A Game Changer*(13:53) The Unique Properties of Astatine-211*(19:27) Global Progress and Future Prospects*(22:45) Challenges and Opportunities in Radiopharmaceuticals--------‘Talk Radioisotopes: Going Nuclear on Cancer’ is brought to you by Nusano, a physics company whose breakthrough technologies are poised to help supply the fight against cancer and enable innovation across multiple industries. Find out more at Nusano.com.--------Links:Follow MiltonVisit Atley SolutionsTalkradioisotopes.com—----